Therapeutics Development Services
The immune system has a very complex series of mechanisms for recognizing pathogens and preventing them from damaging the body. However, when the body's immune system becomes abnormal and produces a sustained immune response to cells of body's own tissues, it will lead to autoimmune diseases and inflammation. Our Company provides leading-edge research services and essential platforms to help you get ahead of the curve in the therapeutics development for autoimmune diseases & inflammation.
Overview of Therapeutic Development
The development of autoimmune diseases and inflammation is a multifactorial, multistage and complex process. Over the past few decades, much progress has been made in the study of the etiology of autoimmune diseases. With the wide application of genetics, biochemistry and molecular biology technologies in the field of new drug development, a large number of novel therapeutic development pipelines have been put into research nowadays. Drugs approved for marketing by the FDA in recent years for the treatment of autoimmune diseases are shown in the table as follows:
FDA Approved Drugs for Autoimmune Diseases Treatment (2021-2023)
| Drugs Name | Active Ingredient | Drug Type | Active Indication | Approved Time |
|---|---|---|---|---|
| Lupkynis | Voclosporin | Small Molecular | To treat lupus nephritis | 1/22/2021 |
| Ponvory | Ponesimod | Small Molecular | To treat relapsing forms of multiple sclerosis | 3/18/2021 |
| Rezurock | Belumosudil | Small Molecular | To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy | 7/16/2021 |
| Bylvay | Odevixibat | Small Molecular | To treat pruritus | 7/20/2021 |
| Saphnelo | Anifrolumab-fnia | Antibody | To treat moderate-to severe systemic lupus erythematosus along with standard therapy | 7/30/2021 |
| Korsuva | Difelikefalin | Small Molecular | To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations | 8/23/2021 |
| Tavneos | Avacopan | Small Molecular | To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids | 10/7/2021 |
| Tezspire | Tezepelumab-ekko | Antibody | To treat severe asthma as an add-on maintenance therapy | 12/17/2021 |
| Vyvgart | Efgartigimod alfa-fcab | Antibody | To treat generalized myasthenia gravis | 12/17/2021 |
| Adbry | Tralokinumab-ldrm | Antibody | To treat moderate-to-severe atopic dermatitis | 12/27/2021 |
| Cibinqo | Abrocitinib | Small Molecular | To treat refractory, moderate-to-severe atopic dermatitis | 1/14/2022 |
| Enjaymo | Sutimlimab-jome | Antibody | To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease | 2/4/2022 |
| Vtama | Tapinarof | Small Molecular | To treat plaque psoriasis | 5/23/2022 |
| Spevigo | Spesolimab-sbzo | Antibody | To treat generalized pustular psoriasis flares | 9/1/2022 |
| Sotyktu | Deucravacitinib | Small Molecular | To treat moderate-to-severe plaque psoriasis | 9/9/2022 |
| Briumvi | Ublituximab-xiiy | Antibody | To treat relapsing forms of multiple sclerosis | 12/28/2022 |
| Miebo | Perfluorohexyloctane | Small Molecular | To treat signs and symptoms of dry eye disease | 5/18/2023 |
| Rystiggo | Rozanolixizumab-noli | Antibody | To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive | 6/26/2023 |
| Velsipity | Etrasimod | Small Molecular | To treat moderately to severely active ulcerative colitis in adults | 10/12/2023 |
| Zilbrysq | Zilucoplan | Small Molecular | To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive | 10/17/2023 |
| Bimzelx | Bimekizumab | Antibody | To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy | 10/17/2023 |
| Omvoh | Mirikizumab-mrkz | Antibody | To treat ulcerative colitis | 10/26/2023 |
From FDA Drug Approvals and Databases
Our Services
With the development of molecular biology technology and its wide application in the medical field, it provides more and more choices and possibilities for the development of novel therapies for autoimmune diseases. Our Company provides therapeutic development services with the support from multidisciplinary experts and utilization of various technological platforms, including but not limited as:
Our Advantages
Advanced Biotechnology
Customizable Design
Competitive Pricing
Best After-sales Service
Staffed by genetics experts and researchers from genetic engineering with solid foundation in therapeutics development, our company is committed to providing you with professional services for the therapeutics development for Autoimmune Diseases & Inflammation. If you are interested in our services, please don't hesitate to contact us.